LMZ(SH:600249)2025-03-27 10:20Financial Performance - The company's operating revenue for 2024 reached ¥1,053,051,877.62, representing a year-on-year increase of 5.82% compared to ¥995,136,283.16 in 2023[23] - The net profit attributable to shareholders for 2024 was ¥81,098,815.85, a significant increase of 255.59% from ¥22,806,658.88 in 2023[23] - The basic earnings per share for 2024 was ¥0.1475, up 255.42% from ¥0.0415 in 2023[24] - The total assets of the company as of the end of 2024 amounted to ¥2,720,923,571.60, reflecting a 3.77% increase from ¥2,621,957,721.33 at the end of 2023[23] - The net cash flow from operating activities for 2024 was ¥14,279,946.49, down 62.78% from ¥38,368,320.17 in 2023[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,947,304.22, a decrease of 37.13% from ¥14,231,151.55 in 2023[23] - The weighted average return on net assets for 2024 was 3.75%, an increase from 1.08% in 2023[24] - The total profit for the period was 110 million RMB, a significant increase of 264.59% year-on-year[34] - Net profit attributable to shareholders reached 81.1 million RMB, up 255.59% compared to the previous year[34] - The net profit after deducting non-recurring gains and losses was 8.95 million RMB[34] - Operating cash flow net amount was 14.28 million RMB[34] Research and Development - The company completed 24 new product R&D and upgrades in oral care and 13 in personal care during 2024[35] - R&D investment increased by approximately 10% year-on-year[35] - The company invested ¥17.33 million in R&D, which is a 10.32% increase from ¥15.71 million in the previous year, reflecting a commitment to enhancing research capabilities[46] - The number of R&D personnel is 170, representing 10.88% of the total workforce, with 19 holding master's degrees[55] - The company completed the drafting and implementation of 3 group standards and 1 industry standard, along with obtaining 7 patents, including 4 invention patents, showcasing its commitment to innovation[74] Market and Sales Performance - The sales revenue from online channels increased by 51.23% year-on-year, reaching approximately ¥69.82 million, while offline sales revenue grew by 3.50%[50] - The company maintained a strong brand presence with its "Two Faces Needle" brand recognized as one of China's most beloved national brands, contributing to its competitive advantage[42] - The company’s revenue from the daily chemical segment reached approximately 800.3 million RMB, with a gross margin of 13.84%[83] - Online sales generated approximately 69.8 million RMB, reflecting a year-over-year increase of 51.23%, while offline sales totaled approximately 970.7 million RMB, with a growth of 3.50%[85] Environmental Responsibility - The company has implemented a comprehensive environmental monitoring plan, including manual and automatic monitoring of various pollutants[161] - Yikang Pharmaceutical emphasizes environmental management and has established an environmental protection work organization to ensure compliance with regulations[165] - The company installed photovoltaic power generation equipment, with an estimated output of approximately 960,000 kW.h in 2024, reducing carbon dioxide emissions by about 745 tons[169] - The company achieved a reduction of polyethylene material usage by 12.5 tons annually through the adoption of FSC-certified biodegradable packaging materials[168] - The company has committed to reducing plastic usage by approximately 500 tons annually by replacing traditional materials with biodegradable alternatives[169] Corporate Governance - The company has established a comprehensive corporate governance structure, ensuring clear responsibilities among decision-making, supervisory, and management bodies[107] - The company treats all shareholders equally, providing equal voting rights and ensuring transparency in shareholder meetings[108] - The company has implemented a performance evaluation and incentive mechanism for middle management, linking compensation to performance outcomes[112] - The company emphasizes investor relations management, ensuring fair disclosure of information and responsiveness to investor inquiries[115] - The company has established specialized committees under the board, including the audit committee, nomination committee, compensation and assessment committee, and strategy committee[131] Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 45,666, an increase from 41,151 at the end of the previous month[191] - The largest shareholder, Guangxi Liuzhou Industrial Investment Development Group Co., Ltd., holds 183,360,652 shares, representing 33.34% of the total shares[192] - Liuzhou Economic Development Investment Co., Ltd. decreased its holdings by 2,525,300 shares, now holding 30,433,867 shares, which is 5.53%[192] - The actual controller of the company is the Liuzhou Municipal Government State-owned Assets Supervision and Administration Commission, established in October 2004[197] Employee Management - The total number of employees in the parent company is 441, while the total number of employees in major subsidiaries is 1,122, resulting in a combined total of 1,563 employees[135] - The company has established a comprehensive training program to enhance employee skills and efficiency, with annual training plans based on departmental needs[137] - The company emphasizes a performance-based compensation system, where higher performance leads to higher salaries, particularly for frontline production and sales staff[136] Dividend Policy - The company plans to distribute a cash dividend of 0.3 RMB per 10 shares, totaling 16,500,000 RMB (including tax) based on a total share capital of 550,000,000 shares as of December 31, 2024[144] - The cash dividend amount represents 20.35% of the net profit attributable to ordinary shareholders in the consolidated financial statements[147] - The company’s cash dividend policy stipulates that at least 10% of the distributable profit must be distributed as cash dividends annually[143] - The board of directors must provide reasons if no cash dividend is proposed despite positive distributable profits[151] Strategic Initiatives - The company aims to integrate the daily chemical and pharmaceutical industries, focusing on becoming a technology-leading enterprise in the health industry[102] - The company plans to enhance brand building and market promotion, deepening its omnichannel marketing strategy to improve profitability and brand value[103] - The company is focusing on strategic planning and investment development, as indicated by the roles of its executives in various investment-related positions[120]